Etodesnitazene

Desnitroetonitazene
Legal status
Legal status	BR: Class F1 (Prohibited narcotics); DE: Anlage II (Authorized trade only, not prescriptible); UK: Under Psychoactive Substances Act; US: Schedule I;
Identifiers
	IUPAC name 2-[2-[(4-Ethoxyphenyl)methyl]benzimidazol-1-yl]-N,N-diethylethanamine;
CAS Number	14030-76-3 ;
PubChem CID	149797386;
UNII	H7YW5L26CS;
KEGG	C22827;
CompTox Dashboard (EPA)	DTXSID601336496 ;
Chemical and physical data
Formula	C22H29N3O
Molar mass	351.494 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCN1C2=CC=CC=C2N=C1CC3=CC=C(C=C3)OCC;
	InChI InChI=1S/C22H29N3O/c1-4-24(5-2)15-16-25-21-10-8-7-9-20(21)23-22(25)17-18-11-13-19(14-12-18)26-6-3/h7-14H,4-6,15-17H2,1-3H3; Key:BMLPNUNXHUGDOI-UHFFFAOYSA-N;

Etodesnitazene (also known as desnitroetonitazene, etazen, etazene, and etazone) is a benzimidazole-derived opioid analgesic drug, which was originally developed in the late 1950s alongside etonitazene and a range of related derivatives.^[1] It is many times less potent than etonitazene itself, but still 70 times more potent than morphine in animal studies. Corresponding analogues where the N,N-diethyl group is replaced by piperidine or pyrrolidine rings also retain significant activity (10 times and 20 times morphine, respectively).^[2] Etodesnitazene has been sold as a designer drug,^[3] first being identified in both Poland and Finland in March 2020.^[4]^[5]

Quick Facts Legal status, Identifiers ...

[1]

[2]

[3]

[4]

[5]

Etodesnitazene

See also

References

Wikiwand - on